Cargando…
Wighteone exhibits an antitumor effect against EGFR L858R/T790M mutation non-small cell lung cancer
Non-small cell lung cancer (NSCLC) harboring activating EGFR mutations were initially treated by first-generation EGFR tyrosine kinase inhibitors (EGFR-TKIs), unfortunately, the efficacy of these drugs is limited, mostly frequent due to T790M mutation. Although osimertinib has been approved to treat...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ivyspring International Publisher
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8176237/ https://www.ncbi.nlm.nih.gov/pubmed/34093797 http://dx.doi.org/10.7150/jca.54574 |
_version_ | 1783703219127451648 |
---|---|
author | Sun, Peiyuan Qu, Yana Wang, Yuna Wang, Jing Wang, Xuanjun Sheng, Jun |
author_facet | Sun, Peiyuan Qu, Yana Wang, Yuna Wang, Jing Wang, Xuanjun Sheng, Jun |
author_sort | Sun, Peiyuan |
collection | PubMed |
description | Non-small cell lung cancer (NSCLC) harboring activating EGFR mutations were initially treated by first-generation EGFR tyrosine kinase inhibitors (EGFR-TKIs), unfortunately, the efficacy of these drugs is limited, mostly frequent due to T790M mutation. Although osimertinib has been approved to treat patients with T790M-positive NSCLC, the majority of patients will develop C797S mutation and suffer diseases again. Therefore, more novel therapeutic strategies for T790M mutation-positive NSCLC are urgently required. We hypothesized that wighteone, a natural compound isolated from plant derivatives, has antitumor effects against NSCLC with T790M mutation. In this study, we created a Ba/F3 cell line harboring EGFR L858R/T790M mutation (Ba/F3 EGFR L858R/T790M cell line), and then used this cell line and a human NSCLC cell line with EGFR L858R/T790M mutation (NCI-H1975) to investigate the effects and mechanism of wighteone. The results showed that wighteone inhibited cell proliferation, suppressed EGFR signaling pathway, caused cell cycle redistribution and induced cell apoptosis. Our studies suggest that wighteone may provide a novel potential therapeutic strategy for NSCLC patients with T790M mutation. |
format | Online Article Text |
id | pubmed-8176237 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Ivyspring International Publisher |
record_format | MEDLINE/PubMed |
spelling | pubmed-81762372021-06-04 Wighteone exhibits an antitumor effect against EGFR L858R/T790M mutation non-small cell lung cancer Sun, Peiyuan Qu, Yana Wang, Yuna Wang, Jing Wang, Xuanjun Sheng, Jun J Cancer Research Paper Non-small cell lung cancer (NSCLC) harboring activating EGFR mutations were initially treated by first-generation EGFR tyrosine kinase inhibitors (EGFR-TKIs), unfortunately, the efficacy of these drugs is limited, mostly frequent due to T790M mutation. Although osimertinib has been approved to treat patients with T790M-positive NSCLC, the majority of patients will develop C797S mutation and suffer diseases again. Therefore, more novel therapeutic strategies for T790M mutation-positive NSCLC are urgently required. We hypothesized that wighteone, a natural compound isolated from plant derivatives, has antitumor effects against NSCLC with T790M mutation. In this study, we created a Ba/F3 cell line harboring EGFR L858R/T790M mutation (Ba/F3 EGFR L858R/T790M cell line), and then used this cell line and a human NSCLC cell line with EGFR L858R/T790M mutation (NCI-H1975) to investigate the effects and mechanism of wighteone. The results showed that wighteone inhibited cell proliferation, suppressed EGFR signaling pathway, caused cell cycle redistribution and induced cell apoptosis. Our studies suggest that wighteone may provide a novel potential therapeutic strategy for NSCLC patients with T790M mutation. Ivyspring International Publisher 2021-05-05 /pmc/articles/PMC8176237/ /pubmed/34093797 http://dx.doi.org/10.7150/jca.54574 Text en © The author(s) https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions. |
spellingShingle | Research Paper Sun, Peiyuan Qu, Yana Wang, Yuna Wang, Jing Wang, Xuanjun Sheng, Jun Wighteone exhibits an antitumor effect against EGFR L858R/T790M mutation non-small cell lung cancer |
title | Wighteone exhibits an antitumor effect against EGFR L858R/T790M mutation non-small cell lung cancer |
title_full | Wighteone exhibits an antitumor effect against EGFR L858R/T790M mutation non-small cell lung cancer |
title_fullStr | Wighteone exhibits an antitumor effect against EGFR L858R/T790M mutation non-small cell lung cancer |
title_full_unstemmed | Wighteone exhibits an antitumor effect against EGFR L858R/T790M mutation non-small cell lung cancer |
title_short | Wighteone exhibits an antitumor effect against EGFR L858R/T790M mutation non-small cell lung cancer |
title_sort | wighteone exhibits an antitumor effect against egfr l858r/t790m mutation non-small cell lung cancer |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8176237/ https://www.ncbi.nlm.nih.gov/pubmed/34093797 http://dx.doi.org/10.7150/jca.54574 |
work_keys_str_mv | AT sunpeiyuan wighteoneexhibitsanantitumoreffectagainstegfrl858rt790mmutationnonsmallcelllungcancer AT quyana wighteoneexhibitsanantitumoreffectagainstegfrl858rt790mmutationnonsmallcelllungcancer AT wangyuna wighteoneexhibitsanantitumoreffectagainstegfrl858rt790mmutationnonsmallcelllungcancer AT wangjing wighteoneexhibitsanantitumoreffectagainstegfrl858rt790mmutationnonsmallcelllungcancer AT wangxuanjun wighteoneexhibitsanantitumoreffectagainstegfrl858rt790mmutationnonsmallcelllungcancer AT shengjun wighteoneexhibitsanantitumoreffectagainstegfrl858rt790mmutationnonsmallcelllungcancer |